Future therapeutic trends in osteoarthritis.

Roy D Altman, P. Kapila, D. D. Dean, D. S. Howell

Research output: Contribution to journalArticle

Abstract

Since cartilage contains no nerve endings, symptoms of osteoarthritis (OA) are indirect. Therapy of OA, to date, has been directed at the symptoms of pain, signs of inflammation and loss of function. A major advance has been surgical joint replacement. This benefit however, is often limited by the joint area involved and to the survival of the endoprosthesis. Orthopedic new approaches to therapy of OA include removal of abnormal tissue to stimulate repair (e.g., burring, abrasion) and grafting (e.g., osteochondral grafts, perichondrium, periosteum) to the subchondral bone. Controlled activity (e.g., passive motion) has been studied alone and with the above. Can a medication retard or reverse the degradative process of OA? Several medications are being examined for potential "chondroprotective" characteristics. Some of these agents are not new: oversulfated glycosaminoglycans (Arteparon) derived from cartilage and glycosaminoglycan peptides (Rumalon) derived from cartilage and bone marrow extracts may be prototypes of this approach to therapy. Other agents demonstrating potential benefit in retarding cartilage degradation may include non-steroidal anti-inflammatory agents, tiaprofenic acid, sodium pentosan sulfate and low dose corticosteroids. This concept of "chondroprotection" provides us a new approach to a disease in need of a new approach.

Original languageEnglish (US)
Pages (from-to)37-42
Number of pages6
JournalScandinavian Journal of Rheumatology, Supplement
Volume77
StatePublished - 1988
Externally publishedYes

Fingerprint

Osteoarthritis
Cartilage
Glycosaminoglycans
Replacement Arthroplasties
Periosteum
Nerve Endings
Non-Steroidal Anti-Inflammatory Agents
Therapeutics
Signs and Symptoms
Orthopedics
Adrenal Cortex Hormones
Joints
Bone Marrow
Inflammation
Transplants
Bone and Bones
Pain
Peptides

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this

Altman, R. D., Kapila, P., Dean, D. D., & Howell, D. S. (1988). Future therapeutic trends in osteoarthritis. Scandinavian Journal of Rheumatology, Supplement, 77, 37-42.

Future therapeutic trends in osteoarthritis. / Altman, Roy D; Kapila, P.; Dean, D. D.; Howell, D. S.

In: Scandinavian Journal of Rheumatology, Supplement, Vol. 77, 1988, p. 37-42.

Research output: Contribution to journalArticle

Altman, RD, Kapila, P, Dean, DD & Howell, DS 1988, 'Future therapeutic trends in osteoarthritis.', Scandinavian Journal of Rheumatology, Supplement, vol. 77, pp. 37-42.
Altman, Roy D ; Kapila, P. ; Dean, D. D. ; Howell, D. S. / Future therapeutic trends in osteoarthritis. In: Scandinavian Journal of Rheumatology, Supplement. 1988 ; Vol. 77. pp. 37-42.
@article{66b4eb2fe8cb4caab644990209725afd,
title = "Future therapeutic trends in osteoarthritis.",
abstract = "Since cartilage contains no nerve endings, symptoms of osteoarthritis (OA) are indirect. Therapy of OA, to date, has been directed at the symptoms of pain, signs of inflammation and loss of function. A major advance has been surgical joint replacement. This benefit however, is often limited by the joint area involved and to the survival of the endoprosthesis. Orthopedic new approaches to therapy of OA include removal of abnormal tissue to stimulate repair (e.g., burring, abrasion) and grafting (e.g., osteochondral grafts, perichondrium, periosteum) to the subchondral bone. Controlled activity (e.g., passive motion) has been studied alone and with the above. Can a medication retard or reverse the degradative process of OA? Several medications are being examined for potential {"}chondroprotective{"} characteristics. Some of these agents are not new: oversulfated glycosaminoglycans (Arteparon) derived from cartilage and glycosaminoglycan peptides (Rumalon) derived from cartilage and bone marrow extracts may be prototypes of this approach to therapy. Other agents demonstrating potential benefit in retarding cartilage degradation may include non-steroidal anti-inflammatory agents, tiaprofenic acid, sodium pentosan sulfate and low dose corticosteroids. This concept of {"}chondroprotection{"} provides us a new approach to a disease in need of a new approach.",
author = "Altman, {Roy D} and P. Kapila and Dean, {D. D.} and Howell, {D. S.}",
year = "1988",
language = "English (US)",
volume = "77",
pages = "37--42",
journal = "Scandinavian Journal of Rheumatology, Supplement",
issn = "0301-3847",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Future therapeutic trends in osteoarthritis.

AU - Altman, Roy D

AU - Kapila, P.

AU - Dean, D. D.

AU - Howell, D. S.

PY - 1988

Y1 - 1988

N2 - Since cartilage contains no nerve endings, symptoms of osteoarthritis (OA) are indirect. Therapy of OA, to date, has been directed at the symptoms of pain, signs of inflammation and loss of function. A major advance has been surgical joint replacement. This benefit however, is often limited by the joint area involved and to the survival of the endoprosthesis. Orthopedic new approaches to therapy of OA include removal of abnormal tissue to stimulate repair (e.g., burring, abrasion) and grafting (e.g., osteochondral grafts, perichondrium, periosteum) to the subchondral bone. Controlled activity (e.g., passive motion) has been studied alone and with the above. Can a medication retard or reverse the degradative process of OA? Several medications are being examined for potential "chondroprotective" characteristics. Some of these agents are not new: oversulfated glycosaminoglycans (Arteparon) derived from cartilage and glycosaminoglycan peptides (Rumalon) derived from cartilage and bone marrow extracts may be prototypes of this approach to therapy. Other agents demonstrating potential benefit in retarding cartilage degradation may include non-steroidal anti-inflammatory agents, tiaprofenic acid, sodium pentosan sulfate and low dose corticosteroids. This concept of "chondroprotection" provides us a new approach to a disease in need of a new approach.

AB - Since cartilage contains no nerve endings, symptoms of osteoarthritis (OA) are indirect. Therapy of OA, to date, has been directed at the symptoms of pain, signs of inflammation and loss of function. A major advance has been surgical joint replacement. This benefit however, is often limited by the joint area involved and to the survival of the endoprosthesis. Orthopedic new approaches to therapy of OA include removal of abnormal tissue to stimulate repair (e.g., burring, abrasion) and grafting (e.g., osteochondral grafts, perichondrium, periosteum) to the subchondral bone. Controlled activity (e.g., passive motion) has been studied alone and with the above. Can a medication retard or reverse the degradative process of OA? Several medications are being examined for potential "chondroprotective" characteristics. Some of these agents are not new: oversulfated glycosaminoglycans (Arteparon) derived from cartilage and glycosaminoglycan peptides (Rumalon) derived from cartilage and bone marrow extracts may be prototypes of this approach to therapy. Other agents demonstrating potential benefit in retarding cartilage degradation may include non-steroidal anti-inflammatory agents, tiaprofenic acid, sodium pentosan sulfate and low dose corticosteroids. This concept of "chondroprotection" provides us a new approach to a disease in need of a new approach.

UR - http://www.scopus.com/inward/record.url?scp=0024564091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024564091&partnerID=8YFLogxK

M3 - Article

C2 - 3070732

VL - 77

SP - 37

EP - 42

JO - Scandinavian Journal of Rheumatology, Supplement

JF - Scandinavian Journal of Rheumatology, Supplement

SN - 0301-3847

ER -